scholarly journals Responsiveness and minimal clinically important difference for the EQ-5D in chronic rhinosinusitis

2019 ◽  
Vol 0 (0) ◽  
pp. 0-0 ◽  
Author(s):  
L.P. Hoehle ◽  
K.M. Phillips ◽  
M.M. Speth ◽  
D.S. Caradonna ◽  
S.T. Gray ◽  
...  
Keyword(s):  
Chronic Rhinosinusitis ◽  
Minimal Clinically Important Difference ◽  
Clinically Important Difference

scholarly journals Investigating the minimal clinically important difference for SNOT-22 symptom domains in surgically managed chronic rhinosinusitis

2017 ◽  
Vol 7 (12) ◽  
pp. 1149-1155 ◽  
Author(s):  
Naweed I. Chowdhury ◽  
Jess C. Mace ◽  
Todd E. Bodner ◽  
Jeremiah A. Alt ◽  
Adam S. Deconde ◽  
...  
Keyword(s):  
Chronic Rhinosinusitis ◽  
Minimal Clinically Important Difference ◽  
Clinically Important Difference ◽  
Symptom Domains ◽  
Snot 22

Multi-institutional minimal clinically important difference of the 22-item Sinonasal Outcome Test in medically managed chronic rhinosinusitis

2021 ◽  
Vol 0 (0) ◽  
pp. 0-0
Author(s):  
K.M. Phillips ◽  
F.A. Houssein ◽  
L.M. Boeckermann ◽  
K.W. Singerman ◽  
D.T. Liu ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Chronic Rhinosinusitis ◽  
General Health ◽  
Nasal Polyps ◽  
Minimal Clinically Important Difference ◽  
Medical Treatments ◽  
Clinically Important Difference ◽  
Sinonasal Outcome Test ◽  
Snot 22

Background: With a rapid proliferation of clinical trials to study novel medical treatments for CRS, the objective of this study was to study the minimal clinically important difference (MCID) of the 22-item Sinonasal Outcome Test (SNOT-22) in medically-managed CRS patients. Methods: A total of 183 medically-treated CRS patients were recruited. All patients completed a SNOT-22 at enrollment and subsequent follow up visit. Distribution and anchor-based methods were used for MCID calculation. These data were combined with data from a previously published study on SNOT-22 MCID in 247 medically managed CRS patients to determine a final recommended MCID value using the combined cohort of 430 patients. Results: In our cohort, distribution- and anchor-based methods—using both sinus-specific and general health anchors—provided greatest support for a 12-point SNOT-22 MCID, which had approximately 55% sensitivity but 81% specificity for detecting patients explicitly reporting improvement in their sinus symptoms and general health. In the combined cohort of 430 patients, we also found greatest support for a 12-point SNOT-22 MCID, which had approximately 57% sensitivity and 81% specificity for detecting patients explicitly reporting improvement in their sinus symptoms and general health. We also find evidence that the MCID value may be higher in CRS patients without nasal polyps compared to those with nasal polyps. Conclusions: Our results - which include data from patients from two different institutions and regions - confirm a SNOT-22 MCID of 12 in medically managed CRS patients. The SNOT-22 MCID was specific but not sensitive for identifying CRS patients experiencing improvement in symptoms or general health.

Minimal clinically important difference for the 22-item Sinonasal Outcome Test in medically managed patients with chronic rhinosinusitis

2018 ◽  
Vol 43 (5) ◽  
pp. 1328-1334 ◽  
Author(s):  
Katie M. Phillips ◽  
Lloyd P. Hoehle ◽  
David S. Caradonna ◽  
Stacey T. Gray ◽  
Ahmad R. Sedaghat
Keyword(s):  
Chronic Rhinosinusitis ◽  
Minimal Clinically Important Difference ◽  
Clinically Important Difference ◽  
Sinonasal Outcome Test

scholarly journals A prospective study to establish the minimal clinically important difference of the Mini-BESTest in individuals with stroke

2021 ◽  
pp. 026921552110251
Author(s):  
Marla K Beauchamp ◽  
Rudy Niebuhr ◽  
Patricia Roche ◽  
Renata Kirkwood ◽  
Kathryn M Sibley
Keyword(s):  
Stroke Rehabilitation ◽  
Minimal Clinically Important Difference ◽  
Clinical Importance ◽  
Minimal Detectable Change ◽  
Global Rating ◽  
Detectable Change ◽  
Clinically Important Difference ◽  
Before And After ◽  
Small Change ◽  
A Prospective Study

Objective: To determine the minimal clinically important difference of the Mini-BESTest in individuals’ post-stroke. Design: Prospective cohort study. Setting: Outpatient stroke rehabilitation. Subjects: Fifty outpatients with stroke with a mean (SD) age of 60.8 (9.4). Intervention: Outpatients with stroke were assessed with the Mini-BESTest before and after a course of conventional rehabilitation. Rehabilitation sessions occurred one to two times/week for one hour and treatment duration was 1.3–42 weeks (mean (SD) = 17.4(10.6)). Main measures: We used a combination of anchor- and distribution-based approaches including a global rating of change in balance scale completed by physiotherapists and patients, the minimal detectable change with 95% confidence, and the optimal cut-point from receiver operating characteristic curves. Results: The average (SD) Mini-BESTest score at admission was 18.2 (6.5) and 22.4 (5.2) at discharge (effect size: 0.7) ( P = 0.001). Mean change scores on the Mini-BESTest for patient and physiotherapist ratings of small change were 4.2 and 4.3 points, and 4.7 and 5.3 points for substantial change, respectively. The minimal detectable change with 95% confidence for the Mini-BESTest was 3.2 points. The minimally clinical importance difference was determined to be 4 points for detecting small changes and 5 points for detecting substantial changes. Conclusions: A change of 4–5 points on the Mini-BEST is required to be perceptible to clinicians and patients, and beyond measurement error. These values can be used to interpret changes in balance in stroke rehabilitation research and practice.

Letter: Contemporary Analysis of Minimal Clinically Important Difference in the Neurosurgical Literature

Neurosurgery ◽  
2021 ◽  
Author(s):  
Sumit Raj ◽  
Pradeep Chouksey ◽  
Adesh Shrivastava ◽  
Rakesh Mishra ◽  
Amit Agrawal
Keyword(s):  
Minimal Clinically Important Difference ◽  
Clinically Important Difference
Sign in / Sign up

Export Citation Format

Share Document